Abstract
The first line of choice for the treatment of infections caused by Methicillin-Resistant Staphylococcus aureus is the antibiotic vancomycin. MRSA strains which do not respond to treatment with vancomycin can be characterized as being either resistant (VRSA) or intermediate (VISA). VISA strains present cell wall thickening as a result of a string of mutations in possibly different sets of…